Identify molecular predictors of risk to objectively validate evolution of dcis

Active Project Grant Awarded Last action

Award ID
HT94252311032
Recipient
Awarding agency
Obligated
$1,712,517

Award facts

Assistance listing
12.420 Military Medical Research and Development
Completion date 77% complete
Place of performance
Great Britain, United Kingdom

Award details come from USAspending.gov.

About this award

Written by GovTribe AI ·

The U.S. Defense Health Agency awarded King's College London a $1,712,517 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to identify molecular predictors of risk and validate the evolution of ductal carcinoma in situ (DCIS) over a 4-year period ending on September 29, 2027. As the prime awardee, King's College London will leverage its expertise in biomedical research to advance the scientific understanding of breast cancer progression. This award supports the program's goals of transforming healthcare for service members and the public through innovative medical research targeting military health needs.

Quick answers

Who received award HT94252311032?

HT94252311032 was awarded to King's College London by Defense Health Agency (Department of Defense) on September 30, 2023.

How much is award HT94252311032 worth?

$1,712,517 has been obligated on HT94252311032.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login